Compare AG & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AG | CYTK |
|---|---|---|
| Founded | 1979 | 1997 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 8.0B |
| IPO Year | N/A | 2004 |
| Metric | AG | CYTK |
|---|---|---|
| Price | $20.41 | $63.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 16 |
| Target Price | $14.25 | ★ $82.38 |
| AVG Volume (30 Days) | ★ 21.5M | 2.2M |
| Earning Date | 02-19-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $965,571,000.00 | $87,211,000.00 |
| Revenue This Year | $107.63 | $339.72 |
| Revenue Next Year | $18.81 | $79.08 |
| P/E Ratio | $125.48 | ★ N/A |
| Revenue Growth | 83.84 | ★ 2609.26 |
| 52 Week Low | $5.09 | $29.31 |
| 52 Week High | $21.12 | $70.98 |
| Indicator | AG | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 70.61 | 50.55 |
| Support Level | $16.77 | $60.30 |
| Resistance Level | $21.12 | $65.08 |
| Average True Range (ATR) | 1.18 | 2.78 |
| MACD | 0.20 | 0.10 |
| Stochastic Oscillator | 87.26 | 60.66 |
First Majestic Silver Corp is engaged in the production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. It owns three producing mines in Mexico consisting of the San Dimas Silver/Gold Mine, the Santa Elena Silver/Gold Mine, and the La Encantada Silver Mine.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.